Raffaele Palmieri

[Raffaele Palmieri @RafPalmieri]

Hey @EHA_Hematology, feel free to invite us at next EHA meeting in Milan! @BrunettiLab

[Raffaele Palmieri @RafPalmieri]

Next EHA in Milan. See you there….maybe #EHA2024

[Raffaele Palmieri @RafPalmieri]

Next EHA in Milan. See you there….maybe #EHA2024

[Raffaele Palmieri @RafPalmieri]

Discussing news from the @EHA_Hematology 2023 meeting at the HME forum organized by Janssen Oncolgy

Link——-> https://t.co/c8PzXnROTT

[VJHemOnc @VJHemOnc]

#ISAL2023 | @RafPalmieri discusses the importance of assessing patient fitness when selecting treatment approaches in AML:

🎥 https://t.co/QzhZw0L7ff

#LeuSM #AMLsm #HemOnc

[Raffaele Palmieri @RafPalmieri]

Thank you @VJHemOnc for the opportunity! https://t.co/YIIlkWDUj4

[VJHemOnc @VJHemOnc]

Last week, we had the pleasure of being in Munich at #ISAL2023, interviewing experts in AML and ALL, who shared some interesting insights & updates.

Check out our interviews here:

🎥: https://t.co/0OhZz1tJdh

#AMLsm #ALLsm #LeuSM #ImmunoOnc #HemOnc #ISALXVIII

[Raffaele Palmieri @RafPalmieri]

Check some of the hottest topic in AML that were discussed during the ISAL2023 in munich #AML #AcuteMyeloieukemia #FitnessAML #MRD ——————> https://t.co/YIIlkWDUj4

[Lorenzo Brunetti @BrunettiLab]

Our own chair @MandyNLauw leading the brainstorming session at the @young_eha committee meeting. Lots of new ideas and projects to develop🌱 @EHA_Hematology

[Raffaele Palmieri @RafPalmieri]

Honoured to present the 6y update of the GIMEMA AML1310 trial at the ISALXVIII 2023 Meeting in Munich @FGIMEMA #Leukemia #AcuteMyeloidLeukemia #AML #MeasurableResidualDisease #MRD

[Francesco Buccisano @FBuccisano]

Francesco Buccisano tells about From MRD monitoring to MRD-driven treatm... https://t.co/H5lg8mpXbf via @YouTube

[Raffaele Palmieri @RafPalmieri]

Incredible opportunity to discuss news from the 2022 ASH meeting in the field of AML (fit and unfit patients).
Thank you @JanssenITA for the opportunity!
The webinar will be online at https://t.co/NJxF9wq8fM for 1 month #FitnessAML #AcuteMyeloidLukemia #ASHmeeting2022

[Raffaele Palmieri @RafPalmieri]

Does the opportunity (to treat) comes once in a lifetime? It’s time to consider Fitness a dynamic parameter https://t.co/sP9BNPIRdR #fitnessAML #acutemyeloidleukemia #leukemia #AML

[Francesco Buccisano @FBuccisano]

First step toward harmonized analysis of #AMLMRD @FGIMEMA @Haematologica @unitorvergata @ptvonline2001

[Lorenzo Brunetti @BrunettiLab]

We cannot assume that all therapy-related myeloid neoplasms have poor outcomes. Genetics matters!
Excited to see this work led by @jadothm finally out. Grateful for the chance to participate in this important study. #leusm

[Raffaele Palmieri @RafPalmieri]

Selecting the right treatment for the right patient. The crucial role of specific aspects of Fitness for treatment selection in Acute Mueloid Leukemia #FitnessAML #AcuteMyeloidLeukemia https://t.co/02Zpeo3Ggg

[Raffaele Palmieri @RafPalmieri]

Focusin on Fitness in Acute Myeloid Leukemia at the ASH2022 meeting #ASH22 #FitnessAML

[Lorenzo Brunetti @BrunettiLab]

Having fun on the stage with the Italian crew after the amazing plenary talks. This is #ASH22! @SIE_Ematologia